AbbVie, Thermo Fisher Scientific, Danaher, SpringWorks Therapeutics, Vertex Pharmaceuticals, Moderna, and GSK are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop and commercialize products using biological processes and technologies—such as genetic engineering, cell therapy and drug discovery—primarily for healthcare, agriculture and environmental applications. These stocks tend to be highly volatile and offer significant growth potential, with share prices often driven by clinical trial outcomes, regulatory approvals and scientific breakthroughs. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of AbbVie stock traded up $0.46 on Friday, reaching $182.14. 2,328,088 shares of the stock were exchanged, compared to its average volume of 7,364,935. The business has a 50 day moving average price of $191.89 and a two-hundred day moving average price of $187.11. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The firm has a market capitalization of $322.20 billion, a price-to-earnings ratio of 75.93, a PEG ratio of 1.62 and a beta of 0.56. AbbVie has a twelve month low of $153.58 and a twelve month high of $218.66.
Read Our Latest Research Report on ABBV
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
TMO stock traded up $3.27 during trading on Friday, hitting $408.20. 799,565 shares of the company traded hands, compared to its average volume of 2,304,087. The stock's 50-day simple moving average is $455.92 and its 200 day simple moving average is $511.36. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The company has a market cap of $154.09 billion, a PE ratio of 24.70, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific has a 1 year low of $390.49 and a 1 year high of $627.88.
Read Our Latest Research Report on TMO
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
DHR stock traded up $2.99 during trading on Friday, hitting $193.94. 1,357,275 shares of the company traded hands, compared to its average volume of 4,413,413. The stock's 50-day simple moving average is $197.06 and its 200 day simple moving average is $217.96. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company has a market cap of $138.80 billion, a PE ratio of 36.74, a P/E/G ratio of 2.66 and a beta of 0.80. Danaher has a 1 year low of $171.00 and a 1 year high of $281.70.
Read Our Latest Research Report on DHR
SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Shares of SpringWorks Therapeutics stock traded up $0.04 on Friday, reaching $46.12. The company's stock had a trading volume of 4,322,032 shares, compared to its average volume of 2,082,325. The company has a market capitalization of $3.46 billion, a P/E ratio of -13.25 and a beta of 0.77. SpringWorks Therapeutics has a 52-week low of $28.21 and a 52-week high of $62.00. The stock has a 50-day moving average price of $44.05 and a 200-day moving average price of $42.05.
Read Our Latest Research Report on SWTX
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of Vertex Pharmaceuticals stock traded down $1.63 on Friday, reaching $432.75. The company's stock had a trading volume of 430,301 shares, compared to its average volume of 1,404,969. The company has a quick ratio of 2.35, a current ratio of 2.69 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a market capitalization of $111.13 billion, a P/E ratio of -196.67, a PEG ratio of 2.11 and a beta of 0.51. The stock has a 50-day moving average price of $483.97 and a 200-day moving average price of $464.73.
Read Our Latest Research Report on VRTX
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of MRNA traded up $1.20 during trading hours on Friday, hitting $24.85. 6,433,682 shares of the stock were exchanged, compared to its average volume of 7,709,759. Moderna has a 12-month low of $23.15 and a 12-month high of $170.47. The company has a market cap of $9.61 billion, a price-to-earnings ratio of -2.68 and a beta of 1.99. The stock's 50-day moving average price is $28.05 and its two-hundred day moving average price is $35.78.
Read Our Latest Research Report on MRNA
GSK (GSK)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Shares of GSK traded up $0.17 during trading hours on Friday, hitting $37.31. 3,794,411 shares of the stock were exchanged, compared to its average volume of 5,339,969. GSK has a 12-month low of $31.72 and a 12-month high of $45.79. The stock's 50-day moving average price is $37.43 and its two-hundred day moving average price is $35.97. The company has a market cap of $76.97 billion, a price-to-earnings ratio of 23.47, a price-to-earnings-growth ratio of 1.12 and a beta of 0.51. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.
Read Our Latest Research Report on GSK
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
